Real-world minimal residual disease assessment in multiple myeloma using a standardized flow cytometry approach: feasibility, clinical implications, and immune correlates from a single-center experience.
Minimal residual disease (MRD) assessment has emerged as a key prognostic marker in multiple myeloma (MM), with MRD negativity (undetectable MRD, uMRD) correlating with improved progression-free and overall survival. The International Myeloma Working Group recommends standardized protocols for MRD detection, including...